Mandelic acid-based spirothiazolidinones targeting M. tuberculosis: Synthesis, in vitro and in silico investigations

Bioorg Chem. 2022 Apr:121:105688. doi: 10.1016/j.bioorg.2022.105688. Epub 2022 Feb 16.

Abstract

A series of new spirothiazolidinone derivatives with a mandelic acid moiety were synthesized and subsequently tested in growth inhibition assays against Mycobacterium tuberculosis strain H37Rv. Compound 16 displayed the highest inhibition value of 98% at lower than 6.25 µg/mL concentration. A single crystal X-ray analysis was conducted on this compound to confirm the structure and determine its absolute configuration. Afterwards, reverse docking and molecular dynamics simulations of this specific stereoisomer were performed against a selection of 10 putative targets of M. tuberculosis to suggest possible mechanisms of action. Our results suggest HadAB, Pks13, DprE1, FadD32 and InhA as possible target proteins for the observed antimycobacterial activity of compound 16.

Keywords: 4-Thiazolidinone; Enoyl-[acyl-carrier-protein]-reductase; Mandelic acid; Molecular docking; Molecular dynamics; MtInhA; Mycobacterium tuberculosis; Spirothiazolidinone.

MeSH terms

  • Antitubercular Agents / chemistry
  • Antitubercular Agents / pharmacology
  • Bacterial Proteins / metabolism
  • Humans
  • Mandelic Acids
  • Microbial Sensitivity Tests
  • Molecular Docking Simulation
  • Mycobacterium tuberculosis* / metabolism
  • Structure-Activity Relationship
  • Tuberculosis*

Substances

  • Antitubercular Agents
  • Bacterial Proteins
  • Mandelic Acids
  • mandelic acid